Table 2. Recommendation of adjuvant treatment for HER2-positive patients after neoadjuvant therapy.
| Condition | Stratification | Level I recommendations | Level II recommendations | Level III recommendations |
|---|---|---|---|---|
| Trastuzumab alone in neoadjuvant | pCR | Trastuzumab + pertuzumab (2A) | Trastuzumab (1B) | |
| Non-pCR | (I) T-DM1 (1A) | Extended adjuvant therapy with neratinib (2B) | ||
| (II) Trastuzumab + pertuzumab (2A) | ||||
| Trastuzumab and pertuzumab in neoadjuvant | pCR | Trastuzumab + pertuzumab (1A) | Trastuzumab (2B) | |
| Non-pCR | (I) T-DM1 (2A) | Extended adjuvant therapy with neratinib (2B) | ||
| (II) Trastuzumab + pertuzumab (2A) |
pCR, pathological complete response; T-DM1, trastuzumab emtansine.